TY - CHAP M1 - Book, Section TI - Metabolic Syndrome A1 - Taylor, Maida A2 - Silverman, Robert K. PY - 2017 T2 - Obesity Medicine: Management of Obesity in Women's Health Care AB - In 1988, at the Banting Lecture at the annual meeting of the American Diabetes Association,1 Dr. Gerald Reaven of Stanford University described a constellation of metabolic abnormalities associated with an increased risk for diabetes and atherosclerotic cardiovascular disease (CVD). This cluster of risk factors was designated “syndrome X,” or insulin resistance syndrome. Dr. Reaven stated that persons with syndrome X2 manifest glucose intolerance, dyslipidemia, abnormal uric acid metabolism, renal salt retention, increased sympathetic tone, and hypercoagulability due to increases in plasminogen activator inhibitor 1 (PAI-1). SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - obgyn.mhmedical.com/content.aspx?aid=1139758822 ER -